A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
Clinical trial NCT07557251 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07557251
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-01
- Primary completion
- 2028-12-01
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.